Sarizotan, a selective 5-HT1A receptor agonist, has been reported to be unable to extend ON time without dyskinesia, and higher dose was related to longer OFF times compared to placebo [106, 107]. This evidence concerns the gene HTR1A and drug-induced dyskinesia.